MA30667B1 - Procedes therapeutiques pour traiter des troubles vasculaires de l'oeil par des antagonistes de dll4. - Google Patents
Procedes therapeutiques pour traiter des troubles vasculaires de l'oeil par des antagonistes de dll4.Info
- Publication number
- MA30667B1 MA30667B1 MA31667A MA31667A MA30667B1 MA 30667 B1 MA30667 B1 MA 30667B1 MA 31667 A MA31667 A MA 31667A MA 31667 A MA31667 A MA 31667A MA 30667 B1 MA30667 B1 MA 30667B1
- Authority
- MA
- Morocco
- Prior art keywords
- ischemic
- dii4
- retinopathy
- organs
- tissues
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Marine Sciences & Fisheries (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un procédé thérapeutique pour traiter les désordres ischémiques ou vasculaires par l'administrant d'un agent capable d'empêcher l'activité delta-like humaine du ligand 4 (DII4) à un sujet ayant besoin. Préférablement, l'agent est un anticorps anti-DII4 ou un fragment de l'anticorps capable d'empêcher l'attache du DII4 à un récepteur Notch. Dans une incorporation, le désordre ischémique ou vasculaire est les blessures ischémiques, l'ischémie cérébrale, l'ischémie cardiaque, les conditions ischémiques affectant les membres et les autres organes ou tissus, les malformations artérielles veineuses, le rétablissement des blessures, la transplantation d'organes ou de tissus, l'insuffisance placentaire, le rétrécissement et l'occlusion artérielle, l'athérosclérose, et l'hypertension systémique ou pulmonaire. Dans une autre incorporation, la maladie traitée est une maladie ou une condition d'oeil telle que la rétinopathie de la prématurité, la rétinopathie ischémique et l'occlusion rétinienne des veines ou d'artères, la rétinopathie diabétique, la néovascularisation choroïde, la dégénération maculaire relative à l'âge, la néovascularisation cornéenne, le glaucome néovasculaire ou la transplantation cornéenne.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83600306P | 2006-08-07 | 2006-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30667B1 true MA30667B1 (fr) | 2009-08-03 |
Family
ID=38904599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31667A MA30667B1 (fr) | 2006-08-07 | 2009-02-26 | Procedes therapeutiques pour traiter des troubles vasculaires de l'oeil par des antagonistes de dll4. |
Country Status (33)
Country | Link |
---|---|
US (1) | US20080181893A1 (fr) |
EP (1) | EP2054082B1 (fr) |
JP (1) | JP5529536B2 (fr) |
KR (1) | KR101497355B1 (fr) |
CN (1) | CN101500605B (fr) |
AU (1) | AU2007281916B2 (fr) |
BR (1) | BRPI0716424B8 (fr) |
CA (1) | CA2660235C (fr) |
CO (1) | CO6150190A2 (fr) |
CR (1) | CR10627A (fr) |
DK (1) | DK2054082T3 (fr) |
ES (1) | ES2398253T3 (fr) |
GT (1) | GT200900029A (fr) |
HK (1) | HK1137339A1 (fr) |
HR (1) | HRP20130271T1 (fr) |
IL (1) | IL196612A (fr) |
MA (1) | MA30667B1 (fr) |
ME (1) | ME00591B (fr) |
MX (1) | MX2009000674A (fr) |
MY (1) | MY150092A (fr) |
NO (1) | NO341857B1 (fr) |
NZ (1) | NZ574794A (fr) |
PL (1) | PL2054082T3 (fr) |
PT (1) | PT2054082E (fr) |
RS (1) | RS52685B (fr) |
RU (1) | RU2429876C2 (fr) |
SG (1) | SG174033A1 (fr) |
SI (1) | SI2054082T1 (fr) |
SV (1) | SV2009003161A (fr) |
TN (1) | TN2009000036A1 (fr) |
UA (1) | UA95304C2 (fr) |
WO (1) | WO2008019144A2 (fr) |
ZA (1) | ZA200900337B (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA018260B1 (ru) | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
JP2010517944A (ja) * | 2007-01-26 | 2010-05-27 | バイオインヴェント インターナショナル アーベー | Dll4シグナリング阻害薬およびその使用 |
GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
BRPI0913476A2 (pt) * | 2008-09-10 | 2015-12-01 | Genentech Inc | "usos de um antagonista tspan12 e usos de um antagonista de norrin" |
US8192738B2 (en) | 2008-09-19 | 2012-06-05 | Medimmune, Llc | Targeted antibodies directed to DLL4 |
CA2742969A1 (fr) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anticorps anti-dll4 et utilisations associees |
WO2011008641A1 (fr) | 2009-07-13 | 2011-01-20 | Beth Israel Deaconess Medical Center, Inc. | Méthodes de modulation de langiogenèse et traitement de maladies associées à langiogenèse |
JP5903382B2 (ja) | 2009-08-29 | 2016-04-13 | アッヴィ・インコーポレイテッド | 治療用dll4結合タンパク質 |
UY32920A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
CN105037543B (zh) * | 2010-03-02 | 2020-11-03 | Abbvie 公司 | 治疗性dll4结合蛋白 |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US8858941B2 (en) | 2011-09-23 | 2014-10-14 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
WO2014062659A2 (fr) * | 2012-10-15 | 2014-04-24 | Oncomed Pharmaceuticals, Inc. | Méthodes de traitement de maladies oculaires |
EP2914961A4 (fr) | 2012-10-31 | 2016-04-20 | Oncomed Pharm Inc | Méthodes et surveillance d'un traitement par un antagoniste de dll4 |
US9931199B2 (en) * | 2014-05-05 | 2018-04-03 | Roberto Gustavo ALBERTAZZI | Methods and apparatus for treating keratoconus |
WO2016070051A2 (fr) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Thérapie combinée pour le traitement d'une maladie |
CN109071644B (zh) | 2015-09-23 | 2023-09-19 | 昂考梅德药品有限公司 | 治疗癌症的方法和组合物 |
US11679126B2 (en) | 2016-11-17 | 2023-06-20 | Chldren's Medical Center Corporation | Methods to enhance microvascular engraftment of bioengineered and primary tissues |
WO2023063842A1 (fr) | 2021-10-12 | 2023-04-20 | Общество с ограниченной ответственностью "Пальмира Биофарма" | Séquence nucléotidique codant une protéine de fusion |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
US20060134121A1 (en) * | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
JP2009507796A (ja) * | 2005-09-01 | 2009-02-26 | バスジーン セラピューティクス, インコーポレイテッド | デルタ様リガンド4のモジュレーターの利用及び同定方法 |
RU2008152435A (ru) * | 2006-06-06 | 2010-07-20 | Дженентек, Инк. (Us) | Композиции и способы регулирования развития сосудов |
-
2007
- 2007-08-07 BR BRPI0716424A patent/BRPI0716424B8/pt active IP Right Grant
- 2007-08-07 US US11/890,741 patent/US20080181893A1/en not_active Abandoned
- 2007-08-07 WO PCT/US2007/017546 patent/WO2008019144A2/fr active Application Filing
- 2007-08-07 KR KR1020097004668A patent/KR101497355B1/ko active IP Right Grant
- 2007-08-07 AU AU2007281916A patent/AU2007281916B2/en active Active
- 2007-08-07 PT PT78111374T patent/PT2054082E/pt unknown
- 2007-08-07 UA UAA200902033A patent/UA95304C2/ru unknown
- 2007-08-07 RU RU2009107921/15A patent/RU2429876C2/ru active
- 2007-08-07 RS RS20130078A patent/RS52685B/en unknown
- 2007-08-07 EP EP07811137A patent/EP2054082B1/fr active Active
- 2007-08-07 SI SI200731170T patent/SI2054082T1/sl unknown
- 2007-08-07 SG SG2011055829A patent/SG174033A1/en unknown
- 2007-08-07 ME MEP-2009-31A patent/ME00591B/fr unknown
- 2007-08-07 CA CA2660235A patent/CA2660235C/fr active Active
- 2007-08-07 DK DK07811137.4T patent/DK2054082T3/da active
- 2007-08-07 ES ES07811137T patent/ES2398253T3/es active Active
- 2007-08-07 MY MYPI20090335A patent/MY150092A/en unknown
- 2007-08-07 NZ NZ574794A patent/NZ574794A/en unknown
- 2007-08-07 MX MX2009000674A patent/MX2009000674A/es active IP Right Grant
- 2007-08-07 PL PL07811137T patent/PL2054082T3/pl unknown
- 2007-08-07 CN CN200780029497.8A patent/CN101500605B/zh active Active
- 2007-08-07 JP JP2009523820A patent/JP5529536B2/ja active Active
-
2009
- 2009-01-15 ZA ZA2009/00337A patent/ZA200900337B/en unknown
- 2009-01-20 IL IL196612A patent/IL196612A/en active IP Right Grant
- 2009-02-03 TN TN2009000036A patent/TN2009000036A1/fr unknown
- 2009-02-05 SV SV2009003161A patent/SV2009003161A/es unknown
- 2009-02-06 GT GT200900029A patent/GT200900029A/es unknown
- 2009-02-20 CR CR10627A patent/CR10627A/es unknown
- 2009-02-26 MA MA31667A patent/MA30667B1/fr unknown
- 2009-03-04 NO NO20090984A patent/NO341857B1/no unknown
- 2009-03-05 CO CO09022898A patent/CO6150190A2/es unknown
-
2010
- 2010-01-29 HK HK10101051.2A patent/HK1137339A1/xx unknown
-
2013
- 2013-03-25 HR HRP20130271TT patent/HRP20130271T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30667B1 (fr) | Procedes therapeutiques pour traiter des troubles vasculaires de l'oeil par des antagonistes de dll4. | |
Patz | Clinical and experimental studies on retinal neovascularization: XXXIX Edward Jackson Memorial Lecture | |
Kiel et al. | Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits | |
Brown et al. | Congenital retinal macrovessels | |
Gunther et al. | Bevacizumab (Avastin) for the treatment of ocular disease | |
Polska et al. | Regulation of choroidal blood flow during combined changes in intraocular pressure and arterial blood pressure | |
Schmidt et al. | Microcatheter urokinase infusion in central retinal artery occlusion | |
Lee et al. | Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab | |
Boltz et al. | Effect of latanoprost on choroidal blood flow regulation in healthy subjects | |
Ozdemir et al. | Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema | |
Chen et al. | Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection | |
Madaan et al. | Müller cell–localized G-protein–coupled receptor 81 (hydroxycarboxylic acid receptor 1) regulates inner retinal vasculature via Norrin/Wnt pathways | |
Amselem et al. | Intravitreal bevacizumab (Avastin) injection in ocular ischemic syndrome | |
An et al. | Neovascular glaucoma due to branch retinal vein occlusion combined with branch retinal artery occlusion | |
Zhu et al. | Effect of enhanced extracorporeal counterpulsation in patients with non-arteritic anterior ischaemic optic neuropathy | |
Lung et al. | Influence of infusion volume on the ocular hemodynamic effects of peribulbar anesthesia | |
ES2324200T3 (es) | Medicamentos oftalmologicos retino-protectores, que comprenden ramipril o ramiprilato. | |
Riva et al. | Microcirculation of the ocular fundus | |
Kayikcioglu et al. | Miliary microemboli of the retinal arterioles and choriocapillaris after subcutaneous injection of triamcinolone acetonide | |
Stefánsson | Diabetic macular edema | |
Froehler et al. | Angiographic investigation of orbital vascular variations in the rabbit and implications for endovascular intra-arterial chemotherapy models | |
Eris et al. | Early retinal and choroidal effect of photodynamic treatment in patients with polypoidal choroidal vasculopathy with or without anti-vascular endothelial growth factor: An optical coherence tomography angiography study | |
ES2275933T3 (es) | Tratamiento de enfermedades oftalmologicas neovasculares. | |
Hayreh et al. | Retinal hemorrhages in malignant arterial hypertension | |
Kurysheva | Vascular theory of the glaucomatous optic neuropathy pathogenesis: the leading concepts of vascular theory. Part 3 |